outset is a pioneering medical technology company that always puts the patient before the machine. our human-centered model is designed to dramatically improve not only the care experience – for patients, families, providers and physicians alike – but also cost-efficiencies for providers. and to achieve this goal, we brought together the most dedicated, creative minds from dialysis with the most dedicated, creative minds from other healthcare fields, in the belief that cross-fertilization – along with hard work – is the surest path to invention. because we believe a dialysis machine should be as easy to use as an everyday consumer product, tablo was designed with simplicity in mind. one example is tablo’s touchscreen display, which offers step-by-step pictures and conversational instructions that make it hard to mess up no matter how new a patient, or caregiver, may be to dialysis. and with simplicity comes speed. we’ve set out to give people their time back. tablo dramatically reduces
Company profile
Ticker
OM
Exchange
Website
CEO
Leslie L. Trigg
Employees
Incorporated
Location
Industry (SIC)
Medtronic • Varian Medical Systems • Conmed • Integer • Masimo • Natus Medical • LivaNova • BioPlus Acquisition • QT Imaging • Fonar ...
Former names
Home Dialysis Plus, Ltd.
SEC CIK
Corporate docs
IRS number
200514392
OM stock data
Latest filings (excl ownership)
8-K
Outset Medical Reports First Quarter 2024 Financial Results
8 May 24
8-K
Outset Medical's TabloCart with Prefiltration Receives FDA 510(k) Clearance
6 May 24
DEFA14A
Additional proxy soliciting materials
11 Apr 24
DEF 14A
Definitive proxy
11 Apr 24
8-K
Outset Medical Announces Appointment of Medical Technology Veteran Brent D. Lang to its Board of Directors
13 Mar 24
S-8
Registration of securities for employees
21 Feb 24
10-K
2023 FY
Annual report
21 Feb 24
8-K
Outset Medical Reports Fourth Quarter and Full Year 2023 Financial Results
21 Feb 24
8-K
Outset Medical Reports Unaudited Fourth Quarter and 2023 Revenue, Provides 2024 Revenue and non-GAAP Gross Margin Guidance
8 Jan 24
8-K
Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
2 Jan 24
Transcripts
OM
Earnings call transcript
2024 Q1
8 May 24
OM
Earnings call transcript
2023 Q3
7 Nov 23
OM
Earnings call transcript
2023 Q3
12 Oct 23
OM
Earnings call transcript
2023 Q2
2 Aug 23
OM
Earnings call transcript
2023 Q2
2 Aug 23
OM
Earnings call transcript
2023 Q1
3 May 23
OM
Earnings call transcript
2022 Q4
13 Feb 23
OM
Earnings call transcript
2022 Q3
9 Nov 22
OM
Earnings call transcript
2022 Q2
5 Aug 22
OM
Earnings call transcript
2022 Q1
5 May 22
Latest ownership filings
4
Nabeel Ahmed
17 May 24
4
Marc Nash
17 May 24
4
John L. Brottem
17 May 24
4
Leslie Trigg
17 May 24
144
Notice of proposed sale of securities
16 May 24
144
Notice of proposed sale of securities
16 May 24
144
Notice of proposed sale of securities
16 May 24
144
Notice of proposed sale of securities
16 May 24
4
Jean-Olivier Racine
10 May 24
144
Notice of proposed sale of securities
10 May 24
Financial summary
Quarter (USD) | Dec 23 | Sep 23 | Jun 23 | Mar 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 71.84 mm | 71.84 mm | 71.84 mm | 71.84 mm | 71.84 mm | 71.84 mm |
Cash burn (monthly) | (no burn) | 391.25 k | 12.83 mm | 14.36 mm | 8.15 mm | 10.95 mm |
Cash used (since last report) | n/a | 1.89 mm | 61.85 mm | 69.21 mm | 39.28 mm | 52.78 mm |
Cash remaining | n/a | 69.95 mm | 9.99 mm | 2.63 mm | 32.56 mm | 19.06 mm |
Runway (months of cash) | n/a | 178.8 | 0.8 | 0.2 | 4.0 | 1.7 |
Institutional ownership, Q4 2023
11.5% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 11 |
Opened positions | 1 |
Closed positions | 143 |
Increased positions | 4 |
Reduced positions | 3 |
13F shares | Current |
---|---|
Total value | 6.43 bn |
Total shares | 5.93 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
JPM JPMorgan Chase & Co. | 4.75 mm | $25.68 mm |
Assenagon Asset Management | 1.02 mm | $5.52 bn |
Griffin Asset Management | 92.61 k | $501.04 mm |
Mirae Asset Global Investments | 21.30 k | $115.21 mm |
Harbor Capital Advisors | 19.97 k | $108.03 mm |
BLB&B Advisors | 15.99 k | $86.48 mm |
Nisa Investment Advisors | 8.79 k | $47.55 mm |
IFP Advisors | 1.98 k | $10.69 mm |
Allspring Global Investments | 1.68 k | $9.08 mm |
Thrivent Trust Co of Tennessee | 26.00 | $0.00 |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
16 May 24 | Leslie Trigg | Common Stock | Sell | Dispose S | No | No | 3.53 | 5,237 | 18.49 k | 915,804 |
16 May 24 | John L. Brottem | Common Stock | Sell | Dispose S | No | No | 3.53 | 2,972 | 10.49 k | 243,875 |
16 May 24 | Marc Nash | Common Stock | Sell | Dispose S | No | No | 3.53 | 1,097 | 3.87 k | 241,413 |
16 May 24 | Nabeel Ahmed | Common Stock | Sell | Dispose S | No | No | 3.53 | 3,918 | 13.83 k | 318,959 |
10 May 24 | Jean-Olivier Racine | Common Stock | Sell | Dispose S | No | No | 3.27 | 8,306 | 27.16 k | 265,325 |
News
Outset Medical Q1 2024 Adj EPS $(0.57) Misses $(0.55) Estimate, Sales $28.168M Miss $30.341M Estimate
8 May 24
12 Health Care Stocks Moving In Wednesday's After-Market Session
8 May 24
Why Outset Medical Shares Are Up Today
6 May 24
12 Health Care Stocks Moving In Monday's Intraday Session
6 May 24
Outset Medical And U.S. Renal Care Announce Multi-Year Agreement To Accelerate And Grow Home Dialysis In U.S.
17 Apr 24
Press releases
Outset Medical Reports First Quarter 2024 Financial Results
8 May 24
Outset Medical's TabloCart with Prefiltration Receives FDA 510(k) Clearance
6 May 24
Outset Medical to Present at Upcoming Investor Conferences
1 May 24
Outset Medical to Report First Quarter 2024 Financial Results on Wednesday, May 8, 2024
19 Apr 24
Outset Medical Partners with American Nephrology Nurses Association to Support Nephrology Nursing and Patient Care
15 Apr 24